FTR is a prodrug metabolized to temsavir (TMR), a first‐in‐class, investigational attachment inhibitor, which binds directly to HIV‐1 gp120 preventing initial attachment to CD4 receptors on T‐cells, and other host immune cells, thereby blocking infection. The gene discussed is CD4; the disease is infection.